TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06449521

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: BECOME intervention
Description: The intervention, BECOME, includes: a) Evidence-based stress reduction (EBSR): as recommended in the WHO mhGAP guidelines, diaphragmatic breathing and body scan will be used to manage stress and anxiety. b) Behavioral activation (BA): as recommended in the mhGAP guidelines, this evidence-based strategy will increase the time that patients spend engaging in pleasurable activities to both treat depression and increase physical activity, depending on their cognitive and physical capabilities (e.g., going to a neighbor's house for tea or walking to the local market). c) Motivational interviewing (MI): an evidence-based patient-interaction strategy that increases the patient's internal motivation to engage in healthy behaviors (e.g., quit tobacco) both to prompt change (if they are not engaging in healthy behaviors) and maintain them (if they are already engaged in healthy behaviors), as recommended by Package of Essential Noncommunicable disease interventions) PEN protocols.
Study: NCT06220279

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diclofenac
Description: Each were monitored for pain within 24 hours

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diclofenac
Description: Each were monitored for pain within 24 hours
Study: NCT06426654

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sintiliman plus LDRT
Description: All patients will start with one cycle of neoadjuvant therapy of sintilimab: sintilimab 200 mg, iv drip, d1, q3w.~LDRT will be performed in the target area. After radiotherapy, patients will receive another three cycles of sintilimab.~Radical D2 gastric cancer resection will be performed 4-6 weeks after the last administration of sintilimab.~The adjuvant therapy will start in 4-6 weeks after the surgery, and we recommend adjuvant treatment with sintilimab for up to 10 cycles.
Study: NCT06342258

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ultradent Ultra Seal XT Plus
Description: Each child who has erupted, bilateral permanent molars that qualify for the study and agree to participate will have a side (right or left side) of their mouth randomized for bond that will be cured prior to sealant placement. Daily flossing and oral hygiene instructions will be taught to patients of all study groups. Sealant will be placed using a dental suction isolation system, such as DryShield isolation after prophy cup polish with pumice. No enameloplasty will be conducted.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ultradent Ultra Seal XT Plus
Description: Each child who has erupted, bilateral permanent molars that qualify for the study and agree to participate will have a side (right or left side) of their mouth randomized for bond that will be cured prior to sealant placement. Daily flossing and oral hygiene instructions will be taught to patients of all study groups. Sealant will be placed using a dental suction isolation system, such as DryShield isolation after prophy cup polish with pumice. No enameloplasty will be conducted.
Study: NCT05732220

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: EMA assessment
Description: Subjects will be asked to complete 3 waves of ecological momentary assessment (EMA) about smoking cues and smoking consumption via mobile phone at the first, second and third month after baseline (total 6 weeks)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EMA assessment
Description: Subjects will be asked to complete 3 waves of ecological momentary assessment (EMA) about smoking cues and smoking consumption via mobile phone at the first, second and third month after baseline (total 6 weeks)
Study: NCT05587140

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acupuncture like TENS
Description: Frequency: 4 Hz, pulse duration: 200 μs, intensity: 3/10 painful sensation with muscle contraction , time: 30 minutes

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Conventional TENS
Description: Frequency: 100 Hz, pulse duration: 200 μs, intensity: strong but comfortable tingling sensation , time: 30 minutes

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham TENS
Description: Frequency: 4 Hz, pulse duration: 200 μs, intensity: tingling sensation, time: turn on the electricity for 15 seconds, then turn off the machine for 30 minutes
Study: NCT05732220

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EMA-based cessation counselling
Description: Subjects will receive tailored peer counselling based on the participants' EMA responses at 1-month and 3-month telephone follow-ups.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual peer counselling
Description: Subjects will receive peer counselling through telephone during follow-ups (usual care), in which the counsellor will apply the 5As model and motivational interviewing techniques.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual peer counselling
Description: Subjects will receive peer counselling through telephone during follow-ups (usual care), in which the counsellor will apply the 5As model and motivational interviewing techniques.
Study: NCT06021470

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive rehabilitation intervention
Description: The intervention comprises a five-week group-based cognitive rehabilitation intervention delivered by a clinical neuropsychologist, with home activities tailored to each stroke survivor's identified goals. Sessions involve four patients and are delivered once per week lasting 2.5 hours with breaks.
Study: NCT05415683

Intervention type: DIAGNOSTIC_TEST
Intervention: DV-SSP Imaging
Description: DeepView utilizes imaging data from DFUs to aid in health care providers' assessment of wound healing potential. It is intended to be used as an aid to health care providers in the management of DFU wounds and not as a standalone prediction device.
Study: NCT04974489

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Emotion-based messages about the harm of VLNC
Description: Participants in this arm will receive 3 emotion-based messages about the harm of VLNC during the survey data collection.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Continued-harm-framed messages about the harm of VLNC
Description: Participants in this arm will receive 3 continued-harm-framed messages about the harm of VLNC during the survey data collection.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Myth-refuting messages about the harm of VLNC
Description: Participants in this arm will receive 3 myth-refuting messages messages about the harm of VLNC during the survey data collection.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control messages about littering
Description: Participants in this arm will receive 3 control messages about littering during the survey data collection.
Study: NCT05718219

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SIM0348
Description: Several dose levels will be evaluated for SIM0348 administered as a single agent . SIM0348 will be given via IV infusion on Day 1,Day 8,Day 15,Day 22 of each cycle (28-day or depending on study cohort and phase) until disease progression or loss of clinical benefit.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SIM0348
Description: Several dose levels will be evaluated for SIM0348 administered as a single agent . SIM0348 will be given via IV infusion on Day 1,Day 8,Day 15,Day 22 of each cycle (28-day or depending on study cohort and phase) until disease progression or loss of clinical benefit.
Study: NCT04656470

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Patients will be delivered dexmedetomidine anesthesia to gain greater understanding of its analgesic effects.
Study: NCT05905289

Intervention type: OTHER
Intervention: observational study
Description: no intervention as it is an observational study
Study: NCT04855929

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ANV419
Description: ANV419 administered by intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ANV419
Description: ANV419 administered by intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Ipilimumab administered by intravenous (IV) infusion
Study: NCT06337422

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Celecoxib 200 mg capsule
Description: Celecoxib 200 mg capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib 200 mg capsule
Description: Celecoxib 200 mg capsule
Study: NCT05909683

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Change of antimicrobials based on BCID2 and Reveal Rapid AST tests. Stop of antimicrobials based on PCT results.
Description: After the patient's blood flask is flagged positive for bloodstream infection, the blood sample will be assessed in the BCID2 diagnostic test in order to identify the underlying pathogens the patient is infected with. After the identification, and in the presence of gram-negative bacteria, the sample will be assessed in the Reveal Rapid AST test to provide information about which antimicrobials the specific pathogens are sensitive to. When both the identification of the pathogen and the sensitivities are available, the central laboratory will inform the attending physicians, who are obliged to change the standard of care antimicrobial therapy administered based on the rule in Box1 of the protocol. Finally, based on the results of the procalcitonin (PCT) on the first day by day 5 when PCT value is less than 80% of the initial value or it remains below 0.5 ng/ml, the attending physicians should discontinue the antimicrobial therapy.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Standard of Care
Description: Standard of care practices of the specific study site. Antimicrobials will be administered based on the attending physicians' critical opinion, and discontinuation will be done based on the standard procedures of the study site.
Study: NCT06418893

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Target control infusion propofol
Description: target control infusion of propofol for target plasma concentration 2.5mcg/ml and BIS 40-60

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Inhalational isoflurane
Description: Inhalational Isoflurane at concentration 1-2%
Study: NCT06331065

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Information session on mindfulness meditation and questionnaires
Description: The information session on mindfulness meditation is an information meeting on the PROMIND study opened to all hospital professionals from the 8 participating departments, i.e. the intervention and control groups.~During this information session, it is specified that it is desirable for the non-intervention groups to maintain their usual practice (or non-practice) during the study, without starting a new practice of mindfulness meditation.~Before this meeting, the baseline questionnaires are administered. Immediately after this time, the questionnaire on representations of mindfulness meditation is administered.
Study: NCT05682261

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: UNIMMAP-MMS
Description: The study participants in this arm will receive the United Nations International Multiple Micronutrient Antenatal Preparation-Multiple Micronutrient Supplements (UNIMMAP-MMS) containing 15 micronutrients including 30 mg of iron and 400 µg of folic acid.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: IFA
Description: The study participants in this arm will receive iron-folic acid supplements with 30 mg of iron and 400 µg of folic acid.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The study participants in this arm will receive placebo made of sugar (lactose anhydrous).
Study: NCT06456931

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Traditional Buddhist mindfulness
Description: Details are provided in the arm/group descriptions.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: secular mindfulness based cognitive therapy
Description: Details are provided in the arm/group descriptions.
Study: NCT06331065

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Information session on mindfulness meditation and questionnaires
Description: The information session on mindfulness meditation is an information meeting on the PROMIND study opened to all hospital professionals from the 8 participating departments, i.e. the intervention and control groups.~During this information session, it is specified that it is desirable for the non-intervention groups to maintain their usual practice (or non-practice) during the study, without starting a new practice of mindfulness meditation.~Before this meeting, the baseline questionnaires are administered. Immediately after this time, the questionnaire on representations of mindfulness meditation is administered.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mindfulness meditation experimentation, practice program, questionnaires, individual interview and focus group
Description: After randomization, a mindfulness meditation trial session is offered to all professionals in the intervention group follow by the questionnaire on representations of mindfulness meditation administration.~Then, interdepartmental focus groups is conducted with leaders. The following mindfulness meditation program consists of 10 1-hour sessions within 15 days, in groups of up to 15 professionals, conducted at the participants' place and time of work, by a certified mindfulness meditation trainer with a recommended daily practice of 10-20 minutes with the possibility of a longer duration, and an audio guidance tool adapted to the study.~After the program, and 3 months later, questionnaires are administered for both groups.~For the intervention group, individual interviews, and inter-departmental focus groups (leaders) are carried out at the end of the intervention, and intra-departmental focus groups are conducted 3 months after the end.
Study: NCT06041698

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Planned Notification
Description: Receive text notification

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Complete surveys

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Intervention
Description: Participate in TXT-Chatbot

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electronic Health Record Review
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interview
Description: Ancillary studies
Study: NCT06570057

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Participatory, learning and Action (PLA) Based intervention
Description: An PLA based intervention would be carried out to prepare the Diabetes Mellitus type II patients. The intervention would be carried out for a tentative time of 2 to 3 hours to educate the type II diabetes mellitus. The study participants would be evaluated after completion of 18 months of the intervention. A structured, validated and literature-based assessment checklist will be devised to assess the effectiveness and feasibility of the intervention.
Study: NCT06041698

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Complete surveys

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Planned Notification
Description: Receive email notification

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Intervention
Description: Participate in MyChart/Patient Portal

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electronic Health Record Review
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interview
Description: Ancillary studies
Study: NCT05620641

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron 8mg
Description: 50 patients will receive intravenous ondansetron 8 mg before the end of surgery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin
Description: 50 patients will receive 600 mg oral gabapentin 1 h before anesthesia.
Study: NCT04732169

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Active study drug ( oral CBD)
Description: CBD in single dose syringes

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: matching placebo
Description: Placebo made with sesame oil flavored with strawberry flavoring in single dose syringes
Study: NCT06154538

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cadonilimab
Description: PD-1/CTLA-4 bi-specific antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOX regimen
Description: FOLFOX chemotherapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FOLFOX regimen
Description: FOLFOX chemotherapy
Study: NCT06406543

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3 (Cholecalciferol)
Description: an oral solution of vitamin D in a refined olive oil solution

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3 (Cholecalciferol)
Description: an oral solution of vitamin D in a refined olive oil solution

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3 (Cholecalciferol)
Description: an oral solution of vitamin D in a refined olive oil solution
Study: NCT03634189

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabidiol
Description: Patients with ACC/AHA stage A-C will receive 5 mg/kg to a maximum tolerated dose of 25 mg/kg PO BID of Cannabidiol
Study: NCT05536284

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bisoprolol Fumarate Tablets
Description: Antihypertensive drug used for acute coronary syndrome patients
Study: NCT06169241

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Beetroot extract
Description: Beetroot extract powder supplementation with 400mg of nitrate per dose in the amount of 10g per day orally will be used in the group.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo will be administered as a colored and flavored isocaloric supplement composed of maltodextrin.
Study: NCT04749693

Intervention type: DEVICE
Intervention: DBLG1 System
Description: Use of DBLG1 System in real life condition
Study: NCT05129670

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Calcite chewing gum
Description: The calcite chewing gum is administered as two pieces of gum in a single dose, 30 minutes following the consumption of a refluxogenic meal.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Unmatched Placebo chewing gum
Description: The placebo chewing gum is administered as two pieces of gum in a single dose, 30 minutes following the consumption of a refluxogenic meal.
Study: NCT06340061

Intervention type: OTHER
Intervention: Observational study
Description: The ocular biomechanical differences between the normal control group and primary glaucoma patients, including those treated with conventional medication, laser therapy, and surgery, were compared. Additionally, an investigation was conducted to explore the relationship between anterior chamber parameters, corneal biomechanics, and the severity of glaucoma
Study: NCT06039488

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: A combination of resistance exercise and cardiovascular exercise (performed 2 days per week for 8-weeks) is tailored to each individual in accordance with their medical/cancer-related history, baseline assessments of physical function, and overall goals.~Resistance exercise includes 6-8 exercises targeting major muscle groups. The first week of the program is used to familiarize participants to the exercises of the program, provide coaching on safe and appropriate technique, and identifying initial load for 2 sets of 12 repetitions (equivalent to \~65% 1 repetition maximum), with a goal of working towards 4 sets of 8 reps. Additionally, participants are asked to perform 20-30 minutes of moderate-to-vigorous aerobic activity (approximately 60-85% age-predicted heart rate maximum) via walking, jogging, or cycling each session.
Study: NCT06244017

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EEG spectrogram
Description: In the experimental group, the general anesthesia is guided by using the EEG spectrogram.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bispectral index
Description: In the control group, the general anesthesia is guided by using the bispectral index
Study: NCT04978597

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Opicapone 50 mg
Description: Capsule, 50 mg, Oral. Swallow whole with water, once daily at bedtime at least 1 hour after L-DOPA/DDCI

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsule of to matching placebo, Oral. Swallow whole with water, once daily at bedtime at least 1 hour after L-DOPA/DDCI
Study: NCT04480372

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine is administered at the dose of 1000 mg/m2 intravenously (i.v.) on day 1 and day 8 of each cycle (every 3 weeks).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab is administered at the dose of 1200 mg i.v. on day 1 of each cycle (every 3 weeks).
Study: NCT02919189

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Visible light exposure
Description: Subjects will be exposed to visible colored light for 15 minutes. The visible light will be generated by fluorescent light lamps.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Visible light exposure
Description: Subjects will be exposed to visible colored light for 15 minutes. The visible light will be generated by fluorescent light lamps.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Visible light exposure
Description: Subjects will be exposed to visible colored light for 15 minutes. The visible light will be generated by fluorescent light lamps.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Visible light exposure
Description: Subjects will be exposed to visible colored light for 15 minutes. The visible light will be generated by fluorescent light lamps.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Visible light exposure
Description: Subjects will be exposed to visible colored light for 15 minutes. The visible light will be generated by fluorescent light lamps.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Visible light exposure
Description: Subjects will be exposed to visible colored light for 15 minutes. The visible light will be generated by fluorescent light lamps.